🇺🇸 FDA
Pipeline program

TNX-103

TNX-103-06

Phase 3 small_molecule active

Quick answer

TNX-103 for Pulmonary Hypertension is a Phase 3 program (small_molecule) at TENAX THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
TENAX THERAPEUTICS, INC.
Indication
Pulmonary Hypertension
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials